This trial is active, not recruiting.

Condition neoplasm malignant
Treatment sar566658
Phase phase 1
Sponsor Sanofi
Start date September 2010
End date June 2017
Trial size 150 participants
Trial identifier NCT01156870, TED10499, U1111-1116-4129


Primary Objective:

To determine the maximum tolerated dose (MTD) of SAR566658

Secondary Objectives:

- To characterize the safety profile of SAR566658

- To evaluate the pharmacokinetic profile of SAR566658

- To assess the potential immunogenicity of SAR566658

- To assess preliminary antitumor activity

- To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam

- To assess safety in the alternative schedules of SAR566658 administration

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
Pharmaceutical form:solution for infusion Route of administration: intravenous

Primary Outcomes

Dose Escalation to determine the maximum tolerated dose (MTD) of SAR566658
time frame: 3 weeks
Extension Cohorts to evaluate the preliminary anti-tumoral effect of SAR566658
time frame: Anticancer activity is assessed every 6 weeks
To assess the effect of SAR566658 at the recommended dose on CYP3A enzyme activity using midazolam as probe
time frame: At D1 and D4 of administration of SAR566658 for 24h of midazolam dosing

Secondary Outcomes

Overall safety profile based on adverse events reporting, laboratory tests, vital signs and specific pulmonary and ocular tests, according to the NCI-CTC AE v4.03
time frame: Up to 2 years
Pharmacokinetic (PK) parameters
time frame: Up to 2 years
Immunogenicity evaluation (anti-drug antibodies)
time frame: Up to 2 years
Antitumoral response
time frame: Up to treatment discontinuation
To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam
time frame: Up to Cycle 2
To assess safety in the alternative schedules of SAR566658 administration
time frame: Up to 2 years

Eligibility Criteria

All participants at least 18 years old.

Inclusion criteria: Diagnosis of CA6-positive solid tumors as moderate to intense membrane staining of ≥15% of tumor cells for which no standard therapy is available. Exclusion criteria: - Eastem Cooperative Oncology Group performance status ≥2. - Any serious active disease or co-morbid condition, which, in the opinion of the Investigator, may interfere with the safety or the compliance with the study. - Poor bone marrow reserve. - Poor liver and renal function. - Pregnant or breast-feeding woman. - No use of effective birth control methods, when applicable. - No resolution of all specific toxicities (excluding alopecia) related to any prior anti-cancer therapy to Grade ≤1 according to the National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 grade scaling. - Wash out period of less than 3 weeks from previous antitumor therapy or any investigational treatment, (and less than 6 weeks in case of prior nitroso-urea and or mitomycin C treatment). Patients will be eligible if hormonotherapy (ie, for breast tumors) is discontinued before first Investigational product administration. - Wash out period of less than 1 week from last palliative dose of radiotherapy. - Patients with respiratory insufficiency defined by a decrease more than 50% compared to theoretical baseline pulmonary volumes and theoretical baseline Diffusing capacity of the Lung for Carbon monoxyde. - Any lung radiotherapy in patient's cancer history. - Patients with previous history or active interstitial lung disease or pulmonary fibrosis. - Patients with abnormal cardiac function defined by a Left Ventricular Ejection Fraction <50%. - Patients with previous history of acute cardiac failure. - Patients with previous history and/or unresolved corneal disorders. - Known intolerance to infused protein products or maytansinoids. - Patients treated with strong CYP3A inhibitors within 2 weeks prior study drug administration. - For patients to be treated in the midazolam cohort: - Any treatment known to induce CYP3A isoenzymes or to inhibit CYP3A4 activities not allowed within 2 weeks before midazolam administration and up to the end of pharmacokinetic sampling following the last midazolam administration. - Any contra-indications to midazolam, according to the applicable labeling. - Patients older than 60 years. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Additional Information

Official title Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors
Description The duration of the study for one patient in the dose escalation phase of the study will include a screening period of up to 3 weeks, a 3-week treatment cycle(s) and a 2-week treatment cycle(s). The patients may continue treatment until disease progression, unacceptable toxicity, or willingness to stop, followed by a minimum of 30-day follow-up. If a patient treated in dose escalation part or in an expansion cohorts, continues to benefit from the treatment at the time of Clinical Study Report, the patient can continue study treatment and will continue to undergo all assessments as per the study flowchart. Such patients will be followed at least until 30 days after the last IMP administration.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Sanofi.